Company / Working Capital
Spero Therapeutics, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$58.4M
FY2025
5-year range
$58.2M / $139.2M
FY2021-FY2025
Trend
+0.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 8 years, ranging from $58M in FY2024 to $139M in FY2021.
Based on SEC 10-K filings.
$58M in FY2025 with a 5-year CAGR of -14.1%.
Declined from $94M to $58M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -14.0%
- 5-Year CAGR
- -14.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.1%, indicating a declining trend.
- In FY2025, working capital increased 0.4% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.4M | +0.4% |
| FY2024 | $58.2M | -38.1% |
| FY2023 | $94.1M | +2.3% |
| FY2022 | $91.9M | -34.0% |
| FY2021 | $139.2M | +11.5% |
| FY2020 | $124.8M | +81.5% |
| FY2019 | $68.8M | -38.6% |
| FY2018 | $111.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026